Research
Evidence, read off the primary source — page 2
No pattern-matched citations and no PMIDs pulled from memory. Every regulatory date, study, and label quote below was fetched live and checked against its primary source before publication — see each article's reference list. 53 articles published so far.
How we verify a source
A PubMed citation is checked against PubMed's own record, not typed from recall. A regulatory page is fetched live and quoted, not paraphrased from a secondary blog. If a claim cannot be verified this way, it is softened or removed — never guessed.
Filter by topic
Showing 25–48 of 53 articles
Evidence review
Is Sermorelin Safe? A Direct Verdict on What the Evidence Actually Shows
Is sermorelin safe? Here's a direct verdict: what its trials found, what its post-marketing record shows, and the real gaps in the evidence that remain.
ReadEvidence review
KPV: What the Evidence Actually Shows
KPV is sold as a gentler, gut-healing peptide. Here's what the rodent colitis research actually found, and why zero human trials have been published.
ReadEvidence review
Melanotan II: What the Evidence Actually Shows
Melanotan II is sold for tanning and libido. Here's what its own trial data and a growing case-report record of melanoma and cardiovascular harm actually show.
ReadEvidence review
MK-677 vs. Sermorelin: What the Evidence and Safety Data Actually Show
MK-677 (ibutamoren) is an oral, non-peptide GH secretagogue with a real safety signal in its own trials — a genuinely different risk profile than sermorelin.
ReadEvidence review
MOTS-c: What the Evidence Actually Shows
MOTS-c is sold as a mitochondrial 'exercise mimetic.' Here's what the mouse data shows, what human studies actually measured, and why CB4211 isn't MOTS-c.
ReadEvidence review
Ozempic Breasts: What Is Actually Happening, and What the Evidence Shows
Breast tissue is largely fat, so rapid GLP-1 weight loss can shrink it. The real mechanism, a quantified estimate, and a live-verified breastfeeding answer.
ReadEvidence review
Ozempic Butt: What Is Actually Happening, and What the Evidence Shows
"Ozempic butt" is the same fat-loss mechanism as Ozempic face. No GLP-1-specific study exists yet, but real body-contouring surgery data shows how common it is.
ReadEvidence review
Ozempic Face: What Is Actually Happening, and What the Evidence Shows
"Ozempic face" is a real, now dermatology-journal-documented phenomenon — but it's facial fat loss from rapid weight loss generally, not a drug-specific effect.
ReadEvidence review
Ozempic Hands: What Is Actually Happening, and What the Evidence Shows
"Ozempic hands" is the same fat-loss mechanism as Ozempic face, applied to the backs of your hands — but with no GLP-1-specific study yet. Here's what's real.
ReadEvidence review
PT-141 (Bremelanotide): What the Evidence Actually Shows
Vyleesi (bremelanotide) has real Phase 3 trial data for one narrow use. Here's what the RECONNECT trials, FDA label, and male-use evidence actually show.
ReadEvidence review
Semaglutide Dosage Chart: What the Wegovy and Ozempic Labels Actually Specify
The semaglutide dosage chart, off the Wegovy and Ozempic labels: two different ladders, the 7.2 mg tier, tablets, missed doses, and the mg/mL conversion.
ReadEvidence review
Sermorelin Before and After: What the Evidence Actually Shows You Can Expect
Sermorelin before and after claims are almost all anecdotal. Here's the actual week-by-week timeline data that exists — and what it doesn't show.
ReadEvidence review
Sermorelin Dosage: What the Evidence and Historical Filings Actually Show
Sermorelin has no current FDA label to quote a dosage from. Here's the real trial-level dosing data that exists, live-verified, and what it doesn't show.
ReadEvidence review
Sermorelin Side Effects and Cancer: What the GH/IGF-1 Evidence Actually Shows
Does sermorelin cause cancer? Sermorelin has no cancer data of its own. Here's what its drug class's FDA label warns, and what the GH-axis evidence shows.
ReadEvidence review
Sermorelin Side Effects: What the Trials, the Class Label, and the Cancer Data Actually Report
Sermorelin has no current FDA label. Here are the side effects its own trials reported, the class label's warnings, and what the cancer data really shows.
ReadEvidence review
Sermorelin vs. Ipamorelin vs. CJC-1295: What the Evidence on Growth-Hormone Secretagogues Actually Shows
Sermorelin vs ipamorelin vs CJC-1295: two share a receptor, one doesn't. None is FDA-approved for what telehealth sells, and all three are banned in sport.
ReadEvidence review
Sermorelin vs. Tesamorelin: What the Evidence and FDA Approval Actually Show
Tesamorelin has one narrow FDA-approved use; sermorelin's own approval was pediatric and is discontinued. No trial compares them directly.
ReadEvidence review
TB-500: What the Evidence Actually Shows
TB-500 is marketed as thymosin beta-4, but it is a different synthetic fragment with almost no human data of its own. Here is what the evidence shows.
ReadEvidence review
Tesamorelin Dosing: What the Egrifta FDA Label Actually Specifies
Tesamorelin's dose is on a real FDA label — 1.4 mg (Egrifta SV) or 1.28 mg (Egrifta WR), daily, for a specific HIV indication. Here's exactly what it says.
ReadEvidence review
Tesamorelin Side Effects: What Egrifta's Own FDA Label Reports
Tesamorelin has a current FDA label, unlike sermorelin. Here's what it warns about — neoplasms, IGF-1, glucose intolerance, and a real statistical tension.
ReadEvidence review
Tirzepatide Dosage Chart: The Titration Ladder the FDA Label Actually Specifies
The tirzepatide dosage chart, read off the Zepbound and Mounjaro labels: the 2.5 to 15 mg ladder, escalation timing, missed doses, and the mg/mL conversion.
ReadEvidence review
Tirzepatide Side Effects: What Its FDA Label and Pivotal Trials Actually Report
Tirzepatide has an FDA label with a boxed warning and real per-dose trial data. Here's what Zepbound, Mounjaro, and their pivotal trials actually reported.
ReadEvidence review
Vyleesi (PT-141) for Women's Libido and HSDD: What the Label and Trials Actually Show
Vyleesi (bremelanotide) is FDA-approved for premenopausal HSDD. Here's what the RECONNECT trials and its own label say — and why this site has no board for it.
ReadEvidence review
What Is Compounded Semaglutide? How It Differs From Wegovy and Ozempic, and the One Problem That Is Unique to It
Compounded semaglutide is not FDA-approved and not a generic. Here is how it differs from Wegovy and Ozempic — including a salt-form problem unique to it.
Read
Nothing matches these filters
No article matches both the search text and the topic selected. Try clearing one of the two filters.